Navigation Links
Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
Date:10/29/2008

SAN MARINO, Calif., Oct. 29 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. Clinical data from on-going studies in Los Angeles, California, indicating dose-dependent tumor control rates and survival benefits with no major toxicity in Rexin-G-treated patients prompted the extension of these clinical trials to the East Coast. Rexin-G has gained orphan drug status from the U.S. FDA for three clinical indications: pancreatic cancer, osteosarcoma and soft tissue sarcoma.

The New York clinical trials will be conducted at the Bruckner Oncology Center in Manhattan, New York with Howard W. Bruckner, M.D. as the Principal Investigator. Dr. Bruckner is a board certified medical oncologist who trained at Yale University School of Medicine and performed research at the NIH with specialists and collaborative groups. Dr. Bruckner is internationally renowned for his work in pancreatic, breast, gastrointestinal, colon, and ovarian cancers and was the first medical oncologist to treat patients with Rexin-G for advanced pancreatic cancer in the United States (Int'l J Oncol 2006). He has served as an Expert Consultant and Safety Monitor for the National Surgical Adjuvant Project for Breast and Bowel Cancers Project (NSABP) sponsored by the National Cancer Institute. For further information concerning these clinical trials in New York, please go to http://www.clinicaltrials.gov and search Epeius-sponsored protocols C07-104 and C07-105.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
2. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
3. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
4. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
5. MEDICA 2008 Returns in November
6. NanoMedicine Summit Returns to Cleveland, September 25-26
7. Cystic Fibrosis Trial In Children Returns Positive Data
8. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
9. Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital
10. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
11. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...NEW YORK, Dec. 1 Reportlinker.com ...ilable in its catalogue: ,, Emerging Clinical ...and the changing healthcare and regulatory environ...Emerging-Clinical-Trial-Locations---Eastern-Europe...egulatory-environment.html ,, Over the last de...
(Date:12/1/2009)... CAMBRIDGE, Mass., Dec. 1 To addre... and to promote its potential, a group of individu...ynthetic Biology Industry Association (SynBIA) in ...e association is to provide a forum for individual...stry, address its opportunities and its challenges...
(Date:12/1/2009)...HANGHAI, Dec. 1 /PRNewswire-Asia/ -- Shanghai Chem..., a leading China-based Contract Research,Organiza...2009 Deloitte,Technology Fast 50 China, ranking 3r...panies in China. The award is a testament to ChemP...m 2006 to 2008. , The results of the 2009...
(Date:12/1/2009)...INGFIELD, Ill., Dec. 1 Prairie Hea...nce that it was recently awarded two statuettes at...v. 13 in New York City. The CLIO Healthcare Awards...the healthcare advertising industry and is an exte...recognized awards competitions for advertising, de...
Breaking Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2
... announces the exclusive licensing of DxS Scorpion...rganisms that reduce yields in biofuel fermentatio...contaminant microbes can increase profitability. ...EB) December 3, 2008 -- ETS has had the exclusive ...y since 2005 and has developed numerous methods to...
...ovember 28, Essilor cancelled 1,600,000 shares, in...t the dilutive impact of Oceane bond conversions a... latest cancellations concerned shares acquired un...ed by the Board of Directors on July,15, 2008 to o...g Oceane bonds,due in 2010. To date, a total of 1....
...ioengineering and Nanotechnology (IBN) have uncove...ich suggest that they could play a vital role in d... the redox properties of IMSs was published in the... a separate study published in Angewandte Chemie ...he first use of these salts to convert carbohydrat...
Other Biology Technology:ETS Laboratories Offers New Process Optimization Tools to the Fuel Ethanol Industry 2New uses for imidazolium salts in medicine and alternative energy 2New uses for imidazolium salts in medicine and alternative energy 3
(Date:12/1/2009)...e is pleased to announce the publication of result...he efficacy and tolerability of its novel, intrana...of chronic rhinosinusitis with nasal polyps in Rh...l and European Rhinologic Societies. , Chronic ...ase that can significantly reduce a patient,s qual...
(Date:12/1/2009)...f Technology has been awarded a U.S. Air Force Cen...rgy harvesting and adaptive materials, and to deve... of the modern warfighter. , The $10.5 million ...ganic Nanostructures and Improved Cognition (BIONI...nneth Sandhage, professors in Georgia Tech,s Schoo...
(Date:12/1/2009)...h University-led international research team has d...the next generation of solar cells. , Scientists...agues from the universities of Wollongong and Ulm ...lar cells with a three-fold increase in energy con...ed tandem dye-sensitised solar cells. , Lead re...
Breaking Biology News(10 mins):New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Air Force Center of Excellence awarded in nanostructures and improved cognition 2Air Force Center of Excellence awarded in nanostructures and improved cognition 3Air Force Center of Excellence awarded in nanostructures and improved cognition 4Innovation puts next-generation solar cells on the horizon 2TGen Drug Development establishes European footprint 10804 1TGen Drug Development establishes European footprint 10804 2Many pregnant women avoid HIV screening in Africa 10802 1Diet Cognitive Ability May Play Role in Heart Disease 61696 1Diet Cognitive Ability May Play Role in Heart Disease 61696 2
... A mouse immune cell that plays dual roles as both...eparate cells, has been discovered by an internati...d France. The discovery has triggered a race amon...titasking cell, which could one day be a target fo...n the same way that intelligence and law enforceme...
... The wood shavings from sawmills can be used to pr...op growth in containers. Moreover, this substrate ...ore economic than other, imported ones such as pea...esearchers at the Public University of Navarre who...rre), have developed this substrate material. The ...
... Researchers at the Virginia Bioinformatics Instit...ity, and Duke University Medical Center have devel...genome-wide scale in the fungal pathogen Alternari...ck spot disease, leading to considerable leaf loss...abbage, and broccoli. , Genomic methods that allo...
Other Biology News:Newly discovered killer cell fights cancer 2Newly discovered killer cell fights cancer 3New organic substrate 2New method enables gene disruption in destructive fungal pathogen 2
Perfusion Pressure Kit - 8 channel from AutoMate Scientific, Inc
Chicken Anti-UCK2 Polyclonal Antibody, Unconjugated from Abcam
Enterokinase from bovine intestine from Sigma-Aldrich
Cap-It from ABgene
Biology Products: